Article
Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.
Nature communications - 8 Jun 2017
Bradley Todd, Pollara Justin, Santra Sampa, Vandergrift Nathan, Pittala Srivamshi, Bailey-Kellogg Chris, Shen Xiaoying, Parks Robert, Goodman Derrick, Eaton Amanda, Balachandran Harikrishnan, Mach Linh V, Saunders Kevin O, Weiner Joshua A, Scearce Richard, Sutherland Laura L, Phogat Sanjay, Tartaglia Jim, Reed Steven G, Hu Shiu-Lok, Theis James F, Pinter Abraham, Montefiori David C, Kepler Thomas B, Peachman Kristina K, Rao Mangala, Michael Nelson L, Suscovich Todd J, Alter Galit, Ackerman Margaret E, Moody M Anthony, Liao Hua-Xin, Tomaras Georgia, Ferrari Guido, Korber Bette T, Haynes Barton F
Abstract excerpt
The RV144 Thai trial HIV-1 vaccine of recombinant poxvirus (ALVAC) and recombinant HIV-1 gp120 subtype B/subtype E (B/E) proteins demonstrated 31% vaccine efficacy. Here we design an ALVAC/Pentavalent B/E/E/E/E vaccine to increase the diversity of gp120 motifs in the immunogen to elicit a broader antibody response and enhance protection. We find that immunization of rhesus macaques with the pentavalent vaccine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
